In glioma cells, miR-138 can inhibit CD44 expression by binding to the 3'-UTR of CD44 mRNA, causing activation of the cell cycle inhibitory factor P27 and nuclear translocation, as well as cell cycle arrest in the G0 or G1 phase, leading to downregulation of the proliferative capacity in glioma cells by inhibiting the CD44/AKT signaling pathway [37, 38]. Here, AKT1 is linked to glioma.